M&A Deal Summary

Grünenthal Acquires Almirall de Mexico S.A. de C.V.

On March 15, 2016, Grünenthal acquired life science company Almirall de Mexico S.A. de C.V.

Acquisition Highlights
  • This is Grünenthal’s 1st transaction in the Life Science sector.
  • This is Grünenthal’s 1st transaction in Spain.

M&A Deal Summary
Date 2016-03-15
Target Almirall de Mexico S.A. de C.V.
Sector Life Science
Buyer(s) Grünenthal
Deal Type Add-on Acquisition

Target

Almirall de Mexico S.A. de C.V.

Barcelona, Spain
Almirall de Mexico, S.A. de C.V. is an international pharmaceutical company develops, produces and markets proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Grünenthal

Aachen, Germany
Category Company
Sector Life Science
DESCRIPTION

Grünenthal GmbH is an independent, family-owned, international research-based pharmaceutical company.

DEAL STATS #
Overall 1 of 8
Sector (Life Science) 1 of 6
Type (Add-on Acquisition) 1 of 6
Country (Spain) 1 of 1
Year (2016) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-16 Thar Pharmaceuticals

Pittsburgh, Pennsylvania, United States

Thar Pharmaceuticals, Inc. is a pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform.

Buy -
Mergr

Product

Company

Legal